Blood Manufacturing: Component Preparation, Storage, and Transportation

Blood Banking and Transfusion Medicine

Volumn , Issue , 2007, Pages 183-204

  Harris, Shealynn B ^a   Hillyer, Christopher D ^b  

^a AMERICAN RED CROSS BLOOD SERVICES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649984773     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06981-9.50017-X     Document Type: Chapter

References (190)

1. Hillyer CD, Josephson CD, Blajchman MA, et al., Bacterial contamination of blood components: risks, strategies, and regulation: Joint ASH and AABB educational session in transfusion medicine. Hematology (Am Soc Hematol Educ Program) 2003:575-589.
2. Wagner SJ Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 2004, 86:157-163.
3. Code of Federal Regulations, 21 CFR 604.3. U.S. Government Printing Office, Washington, D.C., 2005(revised annually).
4. U.S. Food and Drug Administration (CBER). Options for Arm Preparation. Available at. Accessed October 30, 2005. http://www.fda.gov/cber/blood/armpreprev.htm.
5. AABB Association Bulletin #03-07 and #03-10, August 2003.
6. Goldman M, Roy G, Frechette N, et al. Evaluation of donor skin disinfection methods. Transfusion 1997, 37:309-312.
7. Newman BH Blood donor complications after whole-blood donation. Curr Opin Hematol 2004, 11:339-345.
8. Winters JL Complications of donor apheresis. J Clin Apheresis 2005, (Epub ahead of print).
9. McLeod BC, Price TH, Owen H, et al. Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998, 38:938-943.
10. Newman BH, Waxman DA Blood donation-related neurologic needle injury: evaluation of 2 years' worth of data from a large blood center. Transfusion 1996, 36:213-215.
11. Newman B Venipuncture nerve injuries after whole-blood donation. Transfusion 2001, 41:571-572.
12. Horowitz SH Venipuncture-induced causalgia: anatomic relations of upper extremity superficial veins and nerves, and clinical considerations. Transfusion 2000, 40:1036-1040.
13. Horowitz SH Venipuncture-induced neuropathic pain: the clinical syndrome, with comparisons to experimental nerve injury models. Pain 2001, 94:225-229.
14. Despotis GJ, Goodnough LT, Dynis M, et al. Adverse events in platelet apheresis donors: a multivariate analysis in a hospital-based program. Vox Sang 1999, 77:24-32.
15. Popovsky MA, Whitaker B, Arnold NL Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995, 35:734-737.
16. Standard 5.3.2:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
17. Standard 5.3.3:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
18. Standard 5.8:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
19. Szewzyk U, Szewzyk R, Stenstrom TA Growth and survival of Serratia marcescens under aerobic and anaerobic conditions in the presence of materials from blood bags. J Clin Microbiol 1993, 31:1826-1830.
20. Standard 5.7.2:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
21. FDA Guidance for Industry Use of sterile connecting devices in blood bank practices, November 2000. Available at. Accessed October 30, 2005. http://www.fda.gov/cber/gdlns/bbconn.htm.
22. Blajchman MA Bacterial contamination of cellular blood components: risks, sources and control. Vox Sang 2004, 87(Suppl 1):98-103.
23. Wagner SJ, Robinette D, Friedman LI, et al. Diversion of initial blood flow to prevent whole-blood contamination by skin surface bacteria: an in vitro model. Transfusion 2000, 40:335-338.
24. de Korte D, Marcelis JH, Verhoeven AJ, et al. Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections. Vox Sang 2002, 83:13-16.
25. Carmen R The selection of plastic materials for blood bags. Transfus Med Rev 1993, 7:1-10.
26. Murphy S, Sayar SN, Gardner FH Storage of platelet concentrates at 22°C. Blood 1970, 35:549-557.
27. Murphy S, Gardner FH Platelet storage at 22°C: role of gas transport across plastic containers in maintenance of viability. Blood 1975, 46:209-218.
28. Murphy S, Kahn RA, Holme S, et al. Improved storage of platelets for transfusion in a new container. Blood 1982, 60:194-200.
29. Holme S, Heaton A, Momoda G Evaluation of a new, more oxygen-permeable, polyvinylchloride container. Transfusion 1989, 29:159-164.
30. Snyder EL, Pope C, Ferri PM, et al. The effect of mode of agitation and type of plastic bag on storage characteristics and in vivo kinetics of platelet concentrates. Transfusion 1986, 26:125-130.
31. Hogge DE, Thompson BW, Schiffer CA Platelet storage for 7 days in second-generation blood bags. Transfusion 1986, 26:131-135.
32. Sasakawa S, Tokunaga E Physical and chemical changes of ACD-pre-served blood: a comparison of blood in glass bottles and plastic bags. Vox Sang 1976, 31:199-210.
33. Horowitz B, Stryker MH, Waldman AA, et al. Stabilization of red blood cells by the plasticizer, diethylhexylphthalate. Vox Sang 1985, 48:150-155.
34. Estep TN, Pedersen RA, Miller TJ, et al. Characterization of erythrocyte quality during the refrigerated storage of whole blood containing di-(2-ethylhexyl) phthalate. Blood 1984, 64:1270-1276.
35. AuBuchon JP, Estep TN, Davey RJ The effect of the plasticizer di-2-ethylhexyl phthalate on the survival of stored RBCs. Blood 1988, 71:448-452.
36. Jaeger RJ, Rubin RJ Contamination of blood stored in plastic packs. Lancet 1970, 2:151.
37. Rock G, Tocchi M, Ganz PR, et al. Incorporation of plasticizer into red cells during storage. Transfusion 1984, 24:493-498.
38. Rubin RJ, Ness PM What price progress? An update on vinyl plastic bags. Transfusion 1989, 29:358-361.
39. Jacobson MS, Kevy SV, Grand RJ Effects of a plasticizer leached from polyvinyl chloride on the subhuman primate: a consequence of chronic transfusion therapy. J Lab Clin Med 1977, 89:1066-1079.
40. Hillman LS, Goodwin SL, Sherman WR Identification and measurement of plasticizer in neonatal tissues after umbilical catheters and blood products. N Engl J Med 1975, 292:381-386.
41. Kavlock R, Boekelheide K, Chapin R, et al. NTP Center for the Evaluation of Risks to Human Reproduction: phthalates expert panel report on the reproductive and developmental toxicity of di(2-ethylhexyl) phthalate. Reprod Toxicol 2002, 16:529-653.
42. Hess JR, Greenwalt TG Storage of red blood cells: new approaches. Transfus Med Rev 2002, 16:283-295.
43. Scott KL, Lecak J, Acker JP Biopreservation of red blood cells: past, present, and future. Transfus Med Rev 2005, 19:127-142.
44. Valeri CR, Collins FB Physiologic effects of 2,3-DPG-depleted red cells with high affinity for oxygen. J Appl Physiol 1971, 31:823-827.
45. Beutler E, Wood L The in vivo regeneration of red cell 2,3 diphospho-glyceric acid (DPG) after transfusion of stored blood. J Lab Clin Med 1969, 74:300-304.
46. Valeri CR, Hirsch NM Restoration in vivo of erythrocyte adenosine triphosphate, 2,3-diphosphoglycerate, potassium ion, and sodium ion concentrations following the transfusion of acid-citrate-dextrose-stored human red blood cells. J Lab Clin Med 1969, 73:722-733.
47. Hogman CF Preparation and preservation of red cells. Vox Sang 1998, 74(Suppl 2):177-187.
48. Kendrick D Chapter IX. Preservative Solutions Blood. Program in World War II 1964, Office of the Surgeon General, Department of the Army, U.S. Government Printing Office, Washington, D.C.
49. Moroff G, Sohmer PR, Button LN Proposed standardization of methods for determining the 24-hour survival of stored red cells. Transfusion 1984, 24:109-114.
50. Högman CF, Eriksson L, Gong J, et al. Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use. Vox Sang 1993, 65:271-278.
51. Hess JR, Rugg N, Knapp AD, et al. Successful storage of RBCs for 10 weeks in a new additive solution. Transfusion 2000, 40:1012-1016.
52. Hess JR, Rugg N, Knapp AD, et al. Successful storage of RBCs for 9 weeks in a new additive solution. Transfusion 2000, 40:1007-1011.
53. Meryman HT, Hornblower ML, Syring RL Prolonged storage of red cells at 4 degrees C. Transfusion 1986, 26:500-505.
54. Hess JR, Hill HR, Oliver CK, et al. Twelve-week RBC storage. Transfusion 2003, 43:867-872.
55. Ho J, Sibbald WJ, Chin-Yee IH Effects of storage on efficacy of red cell transfusion: when is it not safe?. Crit Care Med 2003, 31(12 Suppl):S687-S697.
56. Leal-Noval SR, Jara-Lopez I, Garcia-Garmendia JL, et al. Influence of erythrocyte concentrate storage time on postsurgical morbidity in cardiac surgery patients. Anesthesiology 2003, 98:815-822.
57. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999, 178:570-572.
58. Marik PE, Sibbald WJ Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993, 269:3024-3029.
59. Purdy FR, Tweeddale MG, Merrick PM Association of mortality with age of blood transfused in septic ICU patients. Can J Anaesth 1997, 44:1256-1261.
60. Hogman CF, Knutson F, Loof H, et al. Improved maintenance of 2,3 DPG and ATP in RBCs stored in a modified additive solution. Transfusion 2002, 42:824-829.
61. Kurup PA, Arun P, Gayathri NS, et al. Modified formulation of CPDA for storage of whole blood, and of SAGM for storage of red blood cells, to maintain the concentration of 2,3-diphosphoglycerate. Vox Sang 2003, 85:253-261.
62. Hogman CF, Eriksson L, Wallvik J, et al. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5CPD Erythro-Sol opti system. Vox Sang 1997, 73:212-219.
63. Ebert R, Stead EA, Gibson JG Response of normal subjects to acute blood loss. Arch Intern Med. 1941, 68:578.
64. Howarth S, Sharpey-Schafer EP Low blood-pressure phases following haemorrhage. Lancet 1947, 1:18.
65. Standard 5.6.6.1.3:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
66. Trudnowski RJ, Rico RC Specific gravity of blood and plasma at 4 and 37°C. Clin Chem 1974, 20:615-616.
67. Simon TL, Hunt WC, Garry PJ Iron supplementation for menstruating female blood donors. Transfusion 1984, 24:469-472.
68. Code of Federal Regulations, 21 CFR 640.3(d): U.S. Government Printing Office, Washington, D.C. (revised annually).
69. Jeffrey G, Adams PC Blood from patients with hereditary hemochromatosis-a wasted resource. Transfusion 1999, 39:549-550.
70. FDA Guidance for Industry: Variances for collections from individuals with hereditary hemochromatosis, August 2001. Available at. Accessed October 30, 2005. http://www.fda.gov/cber/gdlns/hemchrom.pdf.
71. Huh YO, Lichtiger B, Giacco GG, et al. Effect of donation time on platelet concentrates and fresh-frozen plasma. An in vitro study. Vox Sang 1989, 56:21-24.
72. Reiss RF, Katz AJ Platelets and factor VIII as functions of blood collection time. Transfusion 1976, 16:229-231.
73. Technical Manual 2002, AABB, Bethesda, MD. 14th ed. M. Brecher (Ed.).
74. Revised Guidelines for the Collection of Platelets October 1988, U.S. Food and Drug Administration (CBER), Pheresis, Memorandum.
75. U.S. Food and Drug Administration (CBER). Revisions of FDA Memorandum of August 27, 1982: Requirements for Infrequent Plasmapheresis Donors. Memorandum, March 1995.
76. FDA Guidance for Industry. Recommendations for collecting red blood cells by automated apheresis methods, January 2001. Available at. Accessed October 30, 2005. http://www.fda.gov/cber/gdlns/rbcautoph2.pdf.
77. Standard 5.5.3.4:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
78. Standard 5.5.1:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
79. Code of Federal Regulations, 21 CFR 640.65, U.S. Government Printing Office, Washington, D.C., 2005(revised annually).
80. U.S. Food and Drug Administration (CBER). Volume Limits for Automated Collection of Source Plasma. Memorandum, November 1992.
81. Standard 5.5.3.5: Silva MA (ed). Standards for Blood Bank and Transfusion Services, 23rd Edition. Bethesda, MD: AABB, 2004.
82. FDA Draft Guidance for Industry. Collection of platelets by automated methods. September 2005. Accessed November 18, 2005. http://www.fda.gov/cber/gdlns/platelet-auto.pdf.
83. Standard 5.5.4:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
84. Briones MA, Josephson CD, Hillyer CD Granulocyte transfusion: Revisited. Curr Hematol Rep 2003, 2:522-527.
85. Stroncek DF, Clay ME, Herr G, et al. Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997, 3:304-308.
86. MacHida U, Tojo A, Takahashi S, et al. The effect of granulocyte colony-stimulating factor administration in healthy donors before bone marrow harvesting. Br J Haematol 2000, 108:747-753.
87. Liles WC, Huang JE, Llewellyn C, et al. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997, 37:182-187.
88. Einsele H, Northoff H, Neumeister B Granulocyte transfusion. Vox Sang 2004, 87(Suppl 2):205-208.
89. Lee JH, Leitman SF, Klein HG A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collections by centrifugal leukapheresis. Blood 1995, 86:4662-4666.
90. Strauss RG Review of the effects of hydroxyethyl starch on the blood coagulation system. Transfusion 1981, 21:299-302.
91. Trivedi SM, Humphrey RL, Braine HG, et al. Hydroxyethyl starch serum levels in leukapheresis donors measured by modified periodic acid-Schiff staining technique. Transfusion 1984, 24:260-263.
92. Maguire LC, Strauss RG, Koepke JA, et al. The elimination of hydroxyethyl starch from the blood of donors experiencing single or multiple intermittent-flow centrifugation leukapheresis. Transfusion 1981, 21:347-353.
93. Standard 5.6.6.1.2.1:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
94. Standard 5.7.5.8:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
95. Standard 5.7.5.8.1:. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, MD. 23rd Edition. M.A. Silva (Ed.).
96. Laine E, Steadman R, Calhoun L, et al. Comparison of RBCs and FFP with whole blood during liver transplant surgery. Transfusion 2003, 43:322-327.
97. Murphy S, Gardner FH Effect of storage temperature on maintenance of platelet viability-deleterious effect of refrigerated storage. N Engl J Med 1969, 280:1094-1098.
98. Murphy S, Gardner FH Platelet storage at 22°C; metabolic, morphologic, and functional studies. J Clin Invest 1971, 50:370-377.
99. Slichter SJ, Harker LA Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. Br J Haematol 1976, 34:395-402.
100. Kahn RA, Cossette I, Friedman LI Optimum centrifugation conditions for the preparation of platelet and plasma products. Transfusion 1976, 16:162-165.
101. Hogman CF, Eriksson L, Hedlund K, et al. The bottom and top system: a new technique for blood component preparation and storage. Vox Sang 1988, 55:211-217.
102. Murphy S Platelets from pooled buffy coats: an update. Transfusion 2005, 45:634-639.
103. Murphy S, Heaton WA, Rebulla P Platelet production in the Old World-and the New. Transfusion 1996, 36:751-754.
104. Janetzko K, Kluter H, van Waeg G, et al. Fully automated processing of buffy-coat-derived pooled platelet concentrates. Transfusion 2004, 44:1052-1058.
105. Valeri CR Use of rejuvenation solutions in blood preservation. Crit Rev Clin Lab Sci 1982, 17:299-374.
106. Package Insert. Rejuvesol. Braintree, Mass. enCyte Systems, 1997.
107. Valeri CR, Gray AD, Cassidy GP, et al. The 24-hour posttransfusion survival, oxygen transport function, and residual hemolysis of human outdated-rejuvenated red cell concentrates after washing and storage at 4°C for 24 to 72 hours. Transfusion 1984, 24:323-326.
108. Szymanski IO, Teno RA, Lockwood WB, et al. Effect of rejuvenation and frozen storage on 42-day-old AS-1 RBCs. Transfusion 2001, 41:550-555.
109. Valeri CR, Zaroulis CG, Vecchione JJ, et al. Therapeutic effectiveness and safety of outdated human red blood cells rejuvenated to restore oxygen transport function to normal, frozen for 3 to 4 years at -80°C, washed, and stored at 4°C for 24 hours prior to rapid infusion. Transfusion 1980, 20:159-170.
110. Valeri CR, Ragno G, Pivacek LE, et al. An experiment with glycerol-frozen red blood cells stored at -80°C for up to 37 years. Vox Sang 2000, 79:168-174.
111. Umlas J, Jacobson M, Kevy SV Suitable survival and half-life of red cells after frozen storage in excess of 10 years. Transfusion 1991, 31:648-649.
112. Valeri CR, Pivacek LE, Gray AD, et al. The safety and therapeutic effectiveness of human red cells stored at -80°C for as long as 21 years. Transfusion 1989, 29:429-437.
113. Lecak J, Scott K, Young C, et al. Evaluation of red blood cells stored at -80°C in excess of 10 years. Transfusion 2004, 44:1306-1313.
114. Mazur P Freezing of living cells: mechanisms and implications. Am J Physiol 1984, 247(3 Pt 1):C125-C142.
115. Rowe AW, Eyster E, Kellner A Liquid nitrogen preservation of red blood cells for transfusion: a low glycerol-rapid freeze procedure. Cryobiology 1968, 5:119-128.
116. Valeri CR Simplification of the methods for adding and removing glycerol during freeze-preservation of human red blood cells with the high or low glycerol methods: biochemical modification prior to freezing. Transfusion 1975, 15:195-218.
117. Hess JR Red cell freezing and its impact on the supply chain. Transfus Med 2004, 14:1-8.
118. Meryman HT, Hornblower M A method for freezing and washing red blood cells using a high glycerol concentration. Transfusion 1972, 12:145-156.
119. Valeri CR, Ragno G, Pivacek L, et al. In vivo survival of apheresis RBCs, frozen with 40-percent (wt/vol) glycerol, deglycerolized in the ACP 215, and stored at 4°C in AS-3 for up to 21 days. Transfusion 2001, 41:928-932.
120. Valeri CR, Ragno G, Pivacek LE, et al. A multicenter study of in vitro and in vivo values in human RBCs frozen with 40-percent (wt/vol) glycerol and stored after deglycerolization for 15 days at 4°C in AS-3: assessment of RBC processing in the ACP 215. Transfusion 2001, 41:933-939.
121. Valeri CR, Srey R, Tilahun D, et al. The in vitro quality of red blood cells frozen with 40 percent (wt/vol) glycerol at -80°C for 14 years, deglycerolized with the Haemonetics ACP 215, and stored at 4°C in additive solution-1 or additive solution-3 for up to 3 weeks. Transfusion 2004, 44:990-995.
122. Valeri CR, Pivacek LE, Cassidy GP, et al. In vitro and in vivo measurements of human RBCs frozen with glycerol and subjected to various storage temperatures before deglycerolization and storage at 4°C for 3 days. Transfusion 2001, 41:401-405.
123. Hmel PJ, Kennedy A, Quiles JG, et al. Physical and thermal properties of blood storage bags: implications for shipping frozen components on dry ice. Transfusion 2002, 42:836-846.
124. Valeri CR, Lane JP, Srey R, et al. Incidence of breakage of human RBCs frozen with 40-percent wt/vol glycerol using two different methods for storage at -80°C. Transfusion 2003, 43:411-414.
125. Bannai M, Mazda T, Sasakawa S The effects of pH and agitation on platelet preservation. Transfusion 1985, 25:57-59.
126. Hunter S, Nixon J, Murphy S The effect of the interruption of agitation on platelet quality during storage for transfusion. Transfusion 2001, 41:809-814.
127. Brecher ME, Holland PV, Pineda AA, et al. Growth of bacteria in inoculated platelets: implications for bacteria detection and the extension of platelet storage. Transfusion 2000, 40:1308-1312.
128. Goldman M, Blajchman MA Blood product-associated bacterial sepsis. Transfus Med Rev 1991, 5:73-83.
129. Dumont LJ, AuBuchon JP, Whitley P, et al. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002, 42:847-854.
130. Wagner SJ, Robinette D Evaluation of swirling, pH, and glucose tests for the detection of bacterial contamination in platelet concentrates. Transfusion 1996, 36:989-993.
131. Chambers LA, Long KF, Wissel ME, et al. Multisite trial of a pH paper and a pH value of less than 7.0 to screen whole-blood-derived platelets: implications for bacterial detection. Transfusion 2004, 44:1261-1263.
132. Hay SN, Brecher ME Validation of pH and glucose determination for bacteria detection screening in platelet concentrates stored in the Terumo Teruflex XT612 platelet container. Transfusion 2004, 44:1395.
133. Brecher ME, Means N, Jere CS, et al. Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms. Transfusion 2001, 41:477-482.
134. Larsen CP, Ezligini F, Hermansen NO, et al. Six years' experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results. Vox Sang 2005, 88:93-97.
135. AuBuchon JP, Cooper LK, Leach MF, et al. Experience with universal bacterial culturing to detect contamination of apheresis platelet units in a hospital transfusion service. Transfusion 2002, 42:855-861.
136. Vostal JG. FDA's current considerations for 7 day platelets and bacterial detection in single and pooled platelet products, January 25, 2005. Available at. Accessed October 30, 2005. http://www.hhs.gov/bloodsafety/presentations/Vostal-FDAPositionfor7daypl atelets.pdf.
137. Moroff G, Holme S, Dabay MH, et al. Storage of pools of six and eight platelet concentrates. Transfusion 1993, 33:374-378.
138. Snyder EL, Stack G, Napychank P, et al. Storage of pooled platelet concentrates. In vitro and in vivo analysis. Transfusion 1989, 29:390-395.
139. Ferrer F, Rivera J, Corral J, et al. Evaluation of pooled platelet concentrates using prestorage versus poststorage WBC reduction: impact of filtration timing. Transfusion 2000, 40:781-788.
140. Wagner SJ, Robinette D, Nazario M, et al. Bacteria levels in components prepared from deliberately inoculated whole blood held for 8 or 24 hours at 20 to 24 degrees C. Transfusion 1995, 35:911-916.
141. Sweeney JD, Kouttab NM, Holme S, et al. Prestorage pooled whole-blood-derived leukoreduced platelets stored for seven days, preserve acceptable quality and do not show evidence of a mixed lymphocyte reaction. Transfusion 2004, 44:1212-1219.
142. Heddle NM, Barty RL, Sigouin CS, et al. In vitro evaluation of prestorage pooled leukoreduced whole blood-derived platelets stored for up to 7 days. Transfusion 2005, 45:904-910.
143. Heddle NM, Cook RJ, Blajchman MA, et al. Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion 2005, 45:896-903.
144. Tovey LA, Lathe GH Caeruloplasmin and green plasma in women taking oral contraceptives, in pregnant women, and in patients with rheumatoid arthritis. Lancet 1968, 2:596-600.
145. Wolf P, Enlander D, Dalziel J, et al. Green plasma in blood donors. N Engl J Med 1969, 281:205.
146. Practice guidelines for blood component therapy. Anesthesiology 1996, 84:732-747. American Society of Anesthesiologists Task Force on Blood Component Therapy.
147. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004, 126:11-28.
148. Cardigan R, Lawrie AS, Mackie IJ, et al. The quality of fresh-frozen plasma produced from whole blood stored at 4°C overnight. Transfusion 2005, 45:1342-1348.
149. Weisert O, Jeremic M Preservation of coagulation factors V and VIII during collection and subsequent storage of bank blood in ACD-A and CPD solutions. Vox Sang 1973, 24:126-133.
150. Nilsson L, Hedner U, Nilsson IM, et al. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. Transfusion 1983, 23:377-381.
151. Kakaiya RM, Morse EE, Panek S Labile coagulation factors in thawed fresh frozen plasma prepared by two methods. Vox Sang 1984, 46:44-46.
152. O'Neill EM, Rowley J, Hansson-Wicher M, et al. Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion 1999, 39:488-491.
153. Sohmer PR, Bolin RB, Scott RL, et al. Effect of delayed refrigeration on plasma factors in whole blood collected in CPDA-2. Transfusion 1982, 22:488-490.
154. Churchill WH, Schmidt B, Lindsey J, et al. Thawing fresh frozen plasma in a microwave oven. A comparison with thawing in a 37°C waterbath. Am J Clin Pathol 1992, 97:227-232.
155. Rock G, Tackaberry ES, Dunn JG, et al. Rapid controlled thawing of fresh-frozen plasma in a modified microwave oven. Transfusion 1984, 24:60-65.
156. Suontaka AM, Silveira A, Soderstrom T, et al. Occurrence of cold activation of transfusion plasma during storage at +4°C. Vox Sang 2005, 88:172-180.
157. Blomback M, Chmielewska J, Netre C, et al. Activation of blood coagulation, fibrinolytic and kallikrein systems during storage of plasma. Vox Sang 1984, 47:342-355.
158. Buchta C, Felfernig M, Hocker P, et al. Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4°C for 6 days. Vox Sang 2004, 87:182-186.
159. Code of Federal Regulations, 21 CFR 601.22: U.S. Government Publishing Office, Washington, D.C. (revised annually).
160. Code of Federal Regulations 21 CFR 610.40: U.S. Government Printing Office, Washington, D.C. (revised annually).
161. Code of Federal Regulations, 21 CFR 640.65 2005. U.S. Government Printing Office, Washington, D.C. (revised annually).
162. Pantanowitz L, Kruskall MS, Uhl L Cryoprecipitate. Patterns of use. Am J Clin Pathol 2003, 119:874-881.
163. Hughes C, Thomas KB, Schiff P, et al. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate. Transfusion 1988, 28:566-570.
164. McCullough J, Weiblen BJ, Fine D Effects of storage of granulocytes on their fate in vivo. Transfusion 1983, 23:20-24.
165. Glasser L, Lane TA, McCullough J, et al. Neutrophil concentrates: functional considerations, storage, and quality control. J Clin Apher 1983, 1:179-184.
166. FDA Compliance Program Manual. Chapter 42: Blood and Blood Products: Inspection of Licensed and Unlicensed Blood Banks, Brokers, Reference Laboratories, and Contractors - 7342.001. FDA Office of Regulatory Affairs. Available at. Accessed October 12, 2005. http://www.fda.gov/cber/7342001bld.htm.
167. Ratko TA, Cummings JP, Oberman HA, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001, 41:1310-1319.
168. Standard 5.7.4.1. Standards for Blood Bank and Transfusion Services 2004, AABB, Bethesda, Md. 23rd Edition. M.A. Silva (Ed.).
169. Lutz P, Dzik WH Large-volume hemocytometer chamber for accurate counting of white cells (WBCs) in WBC-reduced platelets: Validation and application for quality control of WBC-reduced platelets prepared by apheresis and filtration. Transfusion 1993, 33:409-412.
170. Dzik S, Moroff G, Dumont L A multicenter study evaluating three methods for counting residual WBCs in WBC-reduced blood components: nageotte hemocytometry, flow cytometry, and microfluorometry. Transfusion 2000, 40:513-520.
171. Buck SA, Kickler TS, McGuire M, et al. The utility of platelet washing using an automated procedure for severe platelet allergic reactions. Transfusion 1987, 27:391-393.
172. Vesilind GW, Simpson MB, Shifman MA, et al. Evaluation of a centrifugal blood cell processor for washing platelet concentrates. Transfusion 1988, 28:46-51.
173. Weisbach V, Riego W, Strasser E, et al. The in vitro quality of washed, prestorage leucocyte-depleted red blood cell concentrates. Vox Sang 2004, 87:19-26.
174. Kalmin ND, Brown DJ Platelet washing with a blood cell processor. Transfusion 1982, 22:125-127.
175. Toth CB, Kramer J, Pinter J, et al. IgA content of washed red blood cell concentrates. Vox Sang 1998, 74:13-14.
176. Orlin JB, Ellis MH Transfusion-associated graft-versus-host disease. Curr Opin Hematol 1997, 4:442-448.
177. FDA Guidance for Industry. Gamma irradiation of blood and blood components: a pilot program for licensing, February 2000. Available at. Accessed November 18, 2005. http://www.fda.gov/cber/gdlns/gamma.pdf.
178. Pelszynski MM, Moroff G, Luban NL, et al. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: Implications for preventing transfusion-associated graft-versus-host disease. Blood 1994, 83:1683-1689.
179. Luban NL, Drothler D, Moroff G, et al. Irradiation of platelet components: Inhibition of lymphocyte proliferation assessed by limiting-dilution analysis. Transfusion 2000, 40:348-352.
180. Davey RJ, McCoy NC, Yu M, et al. The effect of prestorage irradiation on posttransfusion red cell survival. Transfusion 1992, 32:525-528.
181. Mintz PD, Anderson G Effect of gamma irradiation on the in vivo recovery of stored red blood cells. Ann Clin Lab Sci 1993, 23:216-220.
182. Hillyer CD, Tiegerman KO, Berkman EM Evaluation of the red cell storage lesion after irradiation in filtered packed red cell units. Transfusion 1991, 31:497-499.
183. U.S. Food and Drug Administration (CBER). Guideline for the Uniform Labeling of Blood and Blood Components, August 1985. Available at. Accessed November 18, 2005. http://www.fda.gov/cber/gdlns/unilabel.pdf.
184. Wallas CH Closing the technology gap with supermarkets: implementation of ISBT 128. Transfusion 2005, 45:1054-1055.
185. FDA Guidance for Industry. Recognition and use of a standard for the uniform labeling of blood and blood components, June 2000. Available at. Accessed November 18, 2005. http://www.fda.gov/cber/gdlns/unilabbld.pdf.
186. AABB Association Bulletin #05-12, October 12, 2005.
187. Ashford P (ed). An Introduction to ISBT 128, 2nd Edition: ICCBBA, Inc, 2002.
188. Federal Register. 68 FR 146 July 30, 2003.
189. Federal Register. 67 FR 53118, August 14, 2002. Available at. Accessed November 18, 2005. http://www.cdc.gov/od/ohs/pdffiles/DOTHazMat8-14-02.pdf.
190. George VM, Pringle TC, Kline L, et al. Development and evaluation of a shipping system for platelet components. Transfusion 1996, 36:335-338.